|Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial|
|By: PR Newswire Association LLC. - 12 Jul 2019||Back to overview list
STOCKHOLM, July 12, 2019 /PRNewswire/ -- Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its first-in-human, clinical phase I, trial with drug candidate T20K, in development for the treatment of multiple sclerosis (MS). The clinical phase I study is estimated to be concluded during the second half of 2019.
The recruitment and screening of healthy male volunteers for Cyxone's first-in-human trial with T20K was initiated in June of this year, following the approval from the relevant authorities in the Netherlands where the study site is located. The study aims to evaluate the safety and tolerability of T20K in humans by assessing the level of T20K in the blood after administering one or two dose-levels of the substance. The first cohort of healthy male volunteers have today received their first dose of T20K through infusion, which will be followed by potentially one additional cohort receiving two doses if needed. Each cohort comprise of eight healthy male volunteers.
Kjell G. Stenberg, CEO of Cyxone, commented, "This is an important moment in our company's development taking us another step closer to the end goal. I am very pleased with our partner QPS Netherlands' swift recruitment and screening of participants to this study and, albeit cautiously, looking forward to the conclusion of the study."
Cyxone's first-in-human study with T20K is estimated to be concluded during the second half of 2019. The company will make a further announcement once the final healthy male volunteer in the second cohort has received his last dose.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Copyright 2019 PR Newswire Association LLC.
|Back to overview list|